Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $4 to $6.
Raymond James Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $6
Raymond James analyst Steven Seedhouse maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $4 to $6.
Related Posts
WhatsApp On Brink Of Monetization, Mark Zuckerberg Says, Offers More Clarity On Metaverse Expenditure
Meta Platforms Inc (NASDAQ: META) CEO Mark Zuckerberg told employees that WhatsApp and Messenger would drive the company's next wave of sales growth to assuage concerns about Meta's finances after its first mass layoffs.
Entergy Q2 EPS $1.78 Beats $1.42 Estimate
Entergy (NYSE:ETR) reported quarterly earnings of $1.78 per share which beat the analyst consensus estimate of $1.42 by 25.35 percent. This is a 32.84 percent increase over earnings of $1.34 per share from the same